I LIPID- undersøgelsen kunne der iagttages en reduktion på 13% i myokardial revaskularisering (bypass eller angioplastik) i pravastatin- gruppen, sammenholdt med 15, 7% i placebogruppen.
In the LIPID study, a decrease in 13% in myocardial revascularisation (bypass or angioplasty) in the pravastatin group compared to 15.7% in the placebo group, was observed.